Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)

The use of modern pharmaceuticals and cardiovascular disease (CVD) treatment methods has increased life expectancy and improved the quality of life of both patients with normal carbohydrate metabolism and diabetes mellitus (DM). This study provides a review of the literature on glycaemic control and...

Full description

Bibliographic Details
Main Authors:	Sergey V. Kakorin, Ruben A. Iskandaryan, Ashot M. Mkrtumyan
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2016-06-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus chronic heart failure (chf) cardiovascular mortality cardiovascular disease (cvd) acute myocardial infarction hyperglycemia glycated hemoglobin metformin sulfonylurea derivates insulin dpp-4 inhibitors sglt-2 inhibitors
Online Access:	https://dia-endojournals.ru/dia/article/viewFile/7564/5869

Similar Items

Hypoglycemic therapy in patients with type 2 diabetes and chronic heart failure
by: S. V Kakorin, et al.
Published: (2014-03-01)

Perspectives on reducing mortality attributed to acute myocardial infarction among patients with type 2 diabetes mellitus in multicenter randomized trials
by: Sergey V. Kakorin, et al.
Published: (2016-04-01)

Chronic heart failure in patients with type 2 diabetes mellitus: prevalence, prognosis
by: S. V Kakorin, et al.
Published: (2015-03-01)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
by: Kiyohiko Takahashi, et al.
Published: (2019-03-01)

Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
by: Marile Santamarina, et al.
Published: (2019-03-01)

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: Tamara Y. Milder, et al.
Published: (2019-01-01)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
by: Hershon KS
Published: (2016-05-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
by: Chun-Ting Yang, et al.
Published: (2020-06-01)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
by: Schernthaner G, et al.
Published: (2017-12-01)

The level of glycemia as a risk factor of cardiovascular diseases
by: Ashot Musaelovich Mkrtumyan
Published: (2010-09-01)

Are the Newer Antidiabetic Agents Worth the Cost?
by: Sudhakar Pemminati, et al.
Published: (2016-03-01)

Cardiovascular outcomes of antidiabetic drugs
by: Ranjit Kumar Nath, et al.
Published: (2021-03-01)

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
by: Yulia A. Nasykhova, et al.
Published: (2020-09-01)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
by: Seon-Ah Cha, et al.
Published: (2017-04-01)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors
by: Christian Brinkmann, et al.
Published: (2021-07-01)

Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
by: Yutaka Seino, et al.
Published: (2021-01-01)

Diabetic nephropathy: newer therapeutic perspectives
by: Krishna C. Keri, et al.
Published: (2018-07-01)

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents
by: Takahiro Oguma, et al.
Published: (2016-12-01)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017-05-01)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
by: Dimitrios Patoulias, et al.
Published: (2021-01-01)

Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-12-01)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
by: Daiji Kawanami, et al.
Published: (2017-05-01)

NEW APPROACHES IN THE TREATMENT OF TYPE 2 DIABETES - TRANSITION FROM GLUCOSE-CENTRED TO PATIENT-CENTRED MODEL
by: Antoaneta Tsvetkova, et al.
Published: (2021-08-01)

Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia
by: Gebrie D, et al.
Published: (2021-07-01)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
by: Atsuo Tahara, et al.
Published: (2016-03-01)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
by: Shen L, et al.
Published: (2021-04-01)

Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
by: Milton Packer
Published: (2020-05-01)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice
by: Atsuo Tahara, et al.
Published: (2016-07-01)

Nephroprotective properties of glucose-lowering drugs
by: Elena V. Pokrovskaya, et al.
Published: (2019-04-01)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01)

Repurposing Antidiabetic Drugs for Cardiovascular Disease
by: Mario Schubert, et al.
Published: (2020-09-01)

Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
by: Da-Peng Zhang, et al.
Published: (2020-01-01)

Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
by: Maria Mirabelli, et al.
Published: (2020-05-01)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
by: Schernthaner G, et al.
Published: (2017-01-01)

Diabetic nephropathy: Time to withhold development and progression - A review
by: Usama A.A. Sharaf El Din, et al.
Published: (2017-07-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)

Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
by: Jasna Klen, et al.
Published: (2021-09-01)